57PThe efficacy and safety of rechallenge with an alternative immune checkpoint inhibitor in metastatic malignant melanoma

Background: Immune checkpoint inhibitors (ICIs) have become standard of care in the management of advanced melanoma. While some evidence suggests that rechallenge in the setting of toxicity with prior ICIs is safe, there is rather limited evidence on the efficacy and safety of rechallenge with alternative ICI in the context of disease progression on initial ICI.

https://ift.tt/2QXbFC7